T1	PROC 78 85	Placebo
#1	AnnotatorNotes T1	C0032042; Placebos; Therapeutic or Preventive Procedure
T2	CHEM 92 102	Adalimumab
#2	AnnotatorNotes T2	C1122087; adalimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	DISO 120 139	Artritis Reumatoide
#3	AnnotatorNotes T3	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T4	CHEM 172 183	Metotrexato
#4	AnnotatorNotes T4	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T5	CHEM 224 235	Metotrexato
#5	AnnotatorNotes T5	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T6	PROC 276 320	Estudio de fase 3, aleatorizado, doble ciego
T7	PROC 344 351	placebo
#6	AnnotatorNotes T7	C0032042; Placebos; Therapeutic or Preventive Procedure
T8	CHEM 358 368	adalimumab
#7	AnnotatorNotes T8	C1122087; adalimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	DISO 384 403	artritis reumatoide
#8	AnnotatorNotes T9	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T10	PROC 431 442	tratamiento
#9	AnnotatorNotes T10	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T11	CHEM 460 463	MTX
#10	AnnotatorNotes T11	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T12	CHEM 527 530	MTX
#11	AnnotatorNotes T12	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T13	CHEM 532 535	MTX
#12	AnnotatorNotes T13	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T14	DISO 563 582	Artritis Reumatoide
#13	AnnotatorNotes T14	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T15	DISO 584 586	AR
#14	AnnotatorNotes T15	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T16	DISO 614 633	Artritis Reumatoide
#15	AnnotatorNotes T16	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T17	DISO 635 637	AR
#16	AnnotatorNotes T17	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T18	PROC 746 757	Diagnóstico
#17	AnnotatorNotes T18	C0011900; Diagnosis; Diagnostic Procedure
T19	DISO 761 763	AR
#18	AnnotatorNotes T19	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T20	CHEM 835 838	MTX
#19	AnnotatorNotes T20	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T21	CHEM 904 911	fármaco
#20	AnnotatorNotes T21	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T22	DISO 991 1006	erosiones óseas
T23	PROC 1013 1024	radiografía
#21	AnnotatorNotes T23	C1306645; Plain x-ray; Diagnostic Procedure | C1962945; Radiographic imaging procedure; Diagnostic Procedure
T24	DISO 1031 1046	erosiones óseas
T25	CHEM 1284 1287	ADA
#22	AnnotatorNotes T25	C1122087; adalimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T26	PROC 1227 1235	tratados
#23	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	DISO 1099 1114	erosiones óseas
T28	CHEM 1380 1387	FARMEsc
#24	AnnotatorNotes T28	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance (?) [fármaco modificador de enfermedad sintético convencional, 'conventional synthetic disease-modifying antirheumatic drugs (DMARD)']
T29	CHEM 1268 1274	FARMEb
T30	CHEM 1397 1400	MTX
#25	AnnotatorNotes T30	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T31	CHEM 1459 1475	inhibidor de JAK
T32	CHEM 1482 1493	tofacitinib
#26	AnnotatorNotes T32	C2930696; tofacitinib; Organic Chemical · Pharmacologic Substance
T33	DISO 1553 1576	artropatía inflamatoria
T34	DISO 1592 1594	AR
#27	AnnotatorNotes T34	C0003873; Rheumatoid Arthritis; Disease or Syndrome
T35	DISO 1628 1658	síndrome de Sjögren secundario
#28	AnnotatorNotes T35	C0151450; Secondary Sjögren's syndrome; Disease or Syndrome
T36	CHEM 66 73	ABT-494
#29	AnnotatorNotes T36	C4308782; ABT-494; Organic Chemical · Pharmacologic Substance
T37	CHEM 332 339	ABT-494
#30	AnnotatorNotes T37	C4308782; ABT-494; Organic Chemical · Pharmacologic Substance
T38	CHEM 447 458	metotrexato
#31	AnnotatorNotes T38	C0025677; methotrexate; Organic Chemical · Pharmacologic Substance
T39	PROC 819 830	tratamiento
#32	AnnotatorNotes T39	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T40	PROC 885 911	administración del fármaco
#33	AnnotatorNotes T40	C3469597; Administration of medication; Therapeutic or Preventive Procedure
T41	ANAT 1001 1006	óseas
#34	AnnotatorNotes T41	C0262950; Skeletal bone; Body Part, Organ, or Organ Component | C0391978; Bone Tissue; Tissue
T42	ANAT 1041 1046	óseas
#35	AnnotatorNotes T42	C0262950; Skeletal bone; Body Part, Organ, or Organ Component | C0391978; Bone Tissue; Tissue
T43	PROC 1070 1087	factor reumatoide
#36	AnnotatorNotes T43	C0201660; Rheumatoid Factor Measurement; Laboratory Procedure
T44	PROC 1089 1091	FR
#37	AnnotatorNotes T44	C0201660; Rheumatoid Factor Measurement; Laboratory Procedure
T45	ANAT 1109 1114	óseas
#38	AnnotatorNotes T45	C0262950; Skeletal bone; Body Part, Organ, or Organ Component | C0391978; Bone Tissue; Tissue
T46	PROC 1139 1194	autoanticuerpos frente a péptidos cíclicos citrulinados
#39	AnnotatorNotes T46	C1318660; Anti-cyclic citrullinated peptide antibody level; Laboratory Procedure
T47	CHEM 1495 1506	baricitinib
#40	AnnotatorNotes T47	C4044947; baricitinib; Organic Chemical · Pharmacologic Substance
T48	CHEM 1509 1519	filgotinib
#41	AnnotatorNotes T48	C4310256; Filgotinib; Organic Chemical · Pharmacologic Substance
T49	Date 13 17	2015
T50	LIVB 106 115	pacientes
#42	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	Dose 154 168	dosis estables
T52	LIVB 372 379	sujetos
#43	AnnotatorNotes T52	C0681850; Study Subject; Group
T53	Dose 468 482	dosis estables
T55	LIVB 691 712	Adulto hombre o mujer
#44	AnnotatorNotes T55	C0001675; Adult; Age Group + C0025266; Male population group; Population Group; + C0043210; Woman; Population Group
T58	Age 718 734	al menos 18 años
T59	Duration 772 781	≥ 3 meses
T60	LIVB 789 796	sujetos
#45	AnnotatorNotes T60	C0681850; Study Subject; Group
T61	Duration 806 815	≥ 3 meses
T62	Route 843 851	vía oral
#46	AnnotatorNotes T62	C1527415; Oral Route of Drug administration; Functional Concept
T63	Route 854 864	parenteral
#47	AnnotatorNotes T63	C1518896; Parenteral Route of Drug Administration; Functional Concept
T64	LIVB 1219 1226	sujetos
#48	AnnotatorNotes T64	C0681850; Study Subject; Group
T65	Neg_cue 1276 1283	excepto
T66	Neg_cue 1389 1396	excepto
T67	LIVB 1308 1317	población
#49	AnnotatorNotes T67	C1257890; Population; Population Group
T54	PROC 1355 1369	dejado recibir
#50	AnnotatorNotes T54	C0850893; stop medication; Therapeutic or Preventive Procedure
T56	Neg_cue 1577 1588	distinta de
A1	Population_data T55 Age
A2	Assertion T25 Negated
A3	Assertion T30 Negated
A4	Status T26 History_of
A5	Status T29 History_of
A6	Status T25 History_of
A7	Status T28 History_of
A8	Status T30 History_of
A9	Status T31 History_of
A10	Status T32 History_of
A11	Status T47 History_of
A12	Status T48 History_of
A13	Status T33 History_of
A14	Status T34 History_of
A15	Assertion T34 Negated
A16	Status T35 History_of
#51	AnnotatorNotes T6	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity
#52	AnnotatorNotes T31	C3854325; Janus kinase inhibitor; Pharmacologic Substance 
#53	AnnotatorNotes T33	C0003864; Arthritis; Disease or Syndrome
T57	Neg_cue 489 491	no
T68	Observation 496 524	respondido de forma adecuada
A17	Assertion T68 Negated
R1	Negation Arg1:T57 Arg2:T68	
R2	Negation Arg1:T65 Arg2:T25	
R3	Negation Arg1:T66 Arg2:T30	
R4	Negation Arg1:T56 Arg2:T34	
#54	AnnotatorNotes T68	C1319171; Medication response; Finding
R5	Overlap Arg1:T68 Arg2:T12	
R6	Overlap Arg1:T68 Arg2:T13	
R7	Experiences Arg1:T50 Arg2:T36	
R8	Experiences Arg1:T50 Arg2:T1	
R9	Experiences Arg1:T50 Arg2:T2	
R10	Experiences Arg1:T50 Arg2:T3	
R11	Experiences Arg1:T50 Arg2:T4	
R13	Has_Dose_or_Strength Arg1:T4 Arg2:T51	
R12	Has_Dose_or_Strength Arg1:T5 Arg2:T51	
T69	Observation 201 221	respuesta inadecuada
#55	AnnotatorNotes T69	C0858218; Inappropriate drug response; Finding
R14	Overlap Arg1:T69 Arg2:T5	
R15	Experiences Arg1:T50 Arg2:T69	
R16	Before Arg1:T4 Arg2:T36	
R17	Before Arg1:T4 Arg2:T1	
R18	Before Arg1:T4 Arg2:T2	
R19	Before Arg1:T5 Arg2:T36	
R20	Before Arg1:T5 Arg2:T1	
R21	Before Arg1:T5 Arg2:T2	
R22	Experiences Arg1:T52 Arg2:T37	
R23	Experiences Arg1:T52 Arg2:T7	
R24	Experiences Arg1:T52 Arg2:T8	
R25	Experiences Arg1:T52 Arg2:T9	
R26	Experiences Arg1:T52 Arg2:T10	
R27	Used_for Arg1:T38 Arg2:T10	
R28	Used_for Arg1:T11 Arg2:T10	
R29	Has_Dose_or_Strength Arg1:T38 Arg2:T53	
R30	Has_Dose_or_Strength Arg1:T11 Arg2:T53	
R31	Experiences Arg1:T52 Arg2:T68	
R32	Experiences Arg1:T52 Arg2:T12	
R33	Experiences Arg1:T52 Arg2:T13	
R34	Before Arg1:T12 Arg2:T37	
R35	Before Arg1:T12 Arg2:T7	
R36	Before Arg1:T12 Arg2:T8	
R37	Before Arg1:T13 Arg2:T37	
R38	Before Arg1:T13 Arg2:T7	
R39	Before Arg1:T13 Arg2:T8	
R40	Before Arg1:T10 Arg2:T37	
R41	Before Arg1:T10 Arg2:T7	
R42	Before Arg1:T10 Arg2:T8	
T70	Quantifier_or_Qualifier 404 410	activa
#56	AnnotatorNotes T70	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R43	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T70	
T71	Quantifier_or_Qualifier 411 427	moderada a grave
#57	AnnotatorNotes T71	C1299393; Moderate to severe; Qualitative Concept
R44	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T71	
T72	Quantifier_or_Qualifier 646 662	moderada a grave
#58	AnnotatorNotes T72	C1299393; Moderate to severe; Qualitative Concept
R45	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T72	
R46	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T72	
T73	Quantifier_or_Qualifier 639 645	activa
#59	AnnotatorNotes T73	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R47	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T73	
R48	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T73	
R49	Has_Age Arg1:T55 Arg2:T58	
R50	Has_Duration_or_Interval Arg1:T19 Arg2:T59	
R51	Experiences Arg1:T60 Arg2:T39	
R52	Used_for Arg1:T20 Arg2:T39	
R53	Has_Duration_or_Interval Arg1:T20 Arg2:T61	
R54	Has_Route_or_Mode Arg1:T20 Arg2:T62	
R55	Has_Route_or_Mode Arg1:T20 Arg2:T63	
R56	Before Arg1:T39 Arg2:T40	
R57	Used_for Arg1:T21 Arg2:T40	
R58	Experiences Arg1:T60 Arg2:T40	
T74	Quantifier_or_Qualifier 987 990	≥ 3
R59	Location_of Arg1:T41 Arg2:T22	
R60	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T74	
T75	Quantifier_or_Qualifier 1027 1030	≥ 1
R62	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T75	
R63	Location_of Arg1:T42 Arg2:T24	
#60	AnnotatorNotes T22	C0587240; Erosion of bone; Pathologic Function
#61	AnnotatorNotes T24	C0587240; Erosion of bone; Pathologic Function
#62	AnnotatorNotes T27	C0587240; Erosion of bone; Pathologic Function
R64	Location_of Arg1:T45 Arg2:T27	
T76	Result_or_Value 1053 1061	positivo
#63	AnnotatorNotes T76	C1446409; Positive; Finding
R67	Has_Result_or_Value Arg1:T43 Arg2:T76	
R68	Has_Result_or_Value Arg1:T44 Arg2:T76	
R69	Overlap Arg1:T24 Arg2:T76	
T77	Quantifier_or_Qualifier 1095 1098	≥ 1
R70	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T77	
T78	Result_or_Value 1121 1129	positivo
#64	AnnotatorNotes T78	C1446409; Positive; Finding
R71	Has_Result_or_Value Arg1:T46 Arg2:T78	
R73	Experiences Arg1:T64 Arg2:T26	
R74	Used_for Arg1:T29 Arg2:T26	
#65	AnnotatorNotes T29	C4055380; Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance
R75	Used_for Arg1:T25 Arg2:T26	
T79	Quantifier_or_Qualifier 1289 1301	hasta el 20%
R76	Has_Quantifier_or_Qualifier Arg1:T67 Arg2:T79	
R77	Experiences Arg1:T67 Arg2:T25	
R78	Used_for Arg1:T28 Arg2:T54	
R79	Used_for Arg1:T30 Arg2:T54	
R61	Overlap Arg1:T27 Arg2:T78	
T80	CONC 1596 1607	Se permiten
R65	Experiences Arg1:T50 Arg2:T5	
A18	Experiencer T50 Patient
A19	Experiencer T52 Patient
A20	Experiencer T55 Patient
A21	Experiencer T60 Patient
A22	Experiencer T64 Patient
A23	Experiencer T67 Patient
